Compare Boston Scientific Corporation (BSX) vs KraneShares Electric Vehicles and Future Mobility (KARS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs KraneShares Electric Vehicles and Future Mobility — how do they compare? Boston Scientific Corporation trades at $42.6 (market cap $66.37B), while KraneShares Electric Vehicles and Future Mobility trades at $30.57. The key difference: KraneShares Electric Vehicles and Future Mobility is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | KARS | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Sector/Thematic |
52-Week High | $108.14 | $38.01 |
52-Week Low | $42.63 | $23.10 |
Enterprise Value | $75.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
KARS trades at $29.72, down 2.8% in the last 24 hours, with technical indicators showing a bearish trend as moving averages signal strong selling pressure. The stock lacks key financial ratio data, but recent news highlights global EV sales growth, particularly in Europe and China, driven by high fuel prices and policy support. However, competition from Chinese automakers and potential US regulatory barriers present challenges.
The outlook for KARS is mixed, with positive industry tailwinds from rising EV adoption offset by technical weakness and competitive risks. Investment opportunities lie in exposure to the expanding EV market, but investors face volatility from geopolitical factors and shifting consumer demand. Caution is warranted given the bearish technical signals and lack of fundamental clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →
